Moderna is trading 4.6% down now at $143.88 after Rothschild & Co. Redburn downgraded the stock from Neutral to Sell, citing valuation concerns following its recent cancer-vaccine-led rally.
- The downgrade is pressuring shares despite broader biotech strength
- The firm raised its price target from $40 to $81 but said the shares remained considerably overvalued
- The $81 target remains well below Wednesday’s $150.81 close